|Tuesday, 8 January 2013, 08:00 HKT|
Source: INC Research, LLC
Raleigh, NC, Jan 8, 2013 - (ACN Newswire) - INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process(R) for delivering reliable results, today reported the completion of its CEO succession plan announced in August 2012.
Effective Jan. 1, 2013, Jamie Macdonald, formerly Chief Operating Officer for the Company, officially assumed the role of INC Research's new Chief Executive Officer. Mr. Macdonald replaced James T. Ogle, who remains with the Company as Chairman of the Board. Alistair Macdonald, previously President, Clinical Development Services, assumed the role of Chief Operating Officer.
"With the completion of these changes and the additional executive appointments made in recent months, INC Research is strategically positioned for continued growth," said James Ogle, Chairman of the Board. "We greatly appreciate Jamie and Alistair's contributions to date and look forward to their future leadership as we continue to advance INC Research as a leading provider of clinical development solutions globally."
"I am excited about 2013 and the opportunities it holds for INC Research and our customers," noted Jamie Macdonald, Chief Executive Officer for the Company. "We will continue to leverage our enhanced global scale, renowned therapeutic capability and enhanced Trusted Process(R) to offer increasingly innovative clinical development solutions that improve efficiency and ultimately lead our customers to make better decisions faster. The future for our industry and our Company has never been brighter and we look forward to continuing to partner with our customers in the delivery of new medicines to market to improve world health."
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical developmentprograms of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process(R) methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
Contact: Lori Dorer, Media +1-513-345-1685
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2013 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.